Skip to main content

Table 2 Costs, health impacts and cost-effectiveness of rotavirus vaccines with comparison to no intervention

From: Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option

Strategy Name

Cost

QALYs

Incremental cost-effectiveness ratio ($/QALY)

No vaccine

7.524391

586.6089

−5.58

LLR vaccine

7.629827

586.0207

0

Rotarix vaccination

8.123035

1061.374

−2308.74

Rotateq vaccination

8.160051

975.9129

990.43

  1. Ratio of additional costs and benefits of a particular strategy compared with the no intervention strategy
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us